Related Experiment Video
Updated: Jun 12, 2025

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells
Published on: March 1, 2024
The actin-binding protein drebrin disrupts NF2-LATS kinases complex assembly to facilitate liver tumorigenesis
Yang Sun1, Henan Wei2, Wentao Yu2
1Sheng Yushou Center of Cell Biology and Immunology, Department of Genetics and Developmental Science, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Minghang, Shanghai, China.
Background And Aims:
The Hippo signaling has emerged as a crucial regulator of tissue homeostasis, regeneration, and tumorigenesis, representing a promising therapeutic target. Neurofibromin 2 (NF2), a component of Hippo signaling, is directly linked to human cancers but has been overlooked as a target for cancer therapy.
Approach And Results:
Through a high-content RNA interference genome-wide screen, the actin-binding protein Drebrin (DBN1) has been identified as a novel modulator of YAP localization. Further investigations have revealed that DBN1 directly interacts with NF2, disrupting the activation of large tumor suppressor kinases (LATS1/2) by competing with LATS kinases for NF2 binding. Consequently, DBN1 knockout considerably promotes YAP nuclear exclusion and repression of target gene expression, thereby preventing cell proliferation and liver tumorigenesis. We identified three lysine residues (K238, K248, and K252) essential for DBN1-NF2 interaction and developed a mutant DBN1 (DBN1-3K mut ) that is defective in NF2 binding and incompetent to trigger NF2-dependent YAP activation and tumorigenesis both in vitro and in vivo. Furthermore, BTP2, a DBN1 inhibitor, successfully restored NF2-LATS kinase binding and elicited potent antitumor activity. The combination of sorafenib and BTP2 exerted synergistic inhibitory effects against HCC.
Conclusions:
Our study identifies a novel DBN1-NF2-LATS axis, and pharmacological inhibition of DBN1 represents a promising alternative intervention targeting the Hippo pathway in cancer treatment.
Insights
Drebrin (DBN1) disrupts Hippo signaling by interacting with Neurofibromin 2 (NF2), inhibiting tumor growth. Inhibiting DBN1 shows promise for cancer therapy by restoring NF2 function.
Area of Science:
- Cell biology
- Molecular oncology
- Signal transduction
Background:
- The Hippo signaling pathway is vital for maintaining tissue homeostasis and is implicated in cancer development.
- Neurofibromin 2 (NF2) is a key component of Hippo signaling and is linked to human cancers, yet it remains an under-explored therapeutic target.
- Understanding novel regulators of Hippo signaling is crucial for developing effective cancer treatments.
Purpose of the Study:
- To identify novel modulators of Hippo signaling pathway components, specifically focusing on Neurofibromin 2 (NF2).
- To investigate the role of Drebrin (DBN1) in regulating YAP localization and its interaction with NF2.
- To explore the therapeutic potential of targeting the DBN1-NF2 interaction in cancer, particularly hepatocellular carcinoma (HCC).
Main Methods:
- Genome-wide RNA interference screen to identify modulators of YAP localization.
- Biochemical assays to confirm DBN1 interaction with NF2 and its effect on LATS kinase activation.
- In vitro and in vivo studies using DBN1 mutants and a DBN1 inhibitor (BTP2) to assess effects on tumorigenesis.
- Combination therapy studies with sorafenib and BTP2 in HCC models.
Main Results:
- Drebrin (DBN1) was identified as a novel regulator of YAP localization, directly interacting with NF2.
- DBN1 binding disrupts NF2 interaction with LATS kinases, leading to YAP activation and promoting liver tumorigenesis.
- A DBN1 mutant (DBN1-3K mut) defective in NF2 binding inhibited YAP activation and tumorigenesis.
- Pharmacological inhibition of DBN1 with BTP2 restored NF2-LATS binding and demonstrated antitumor activity, synergizing with sorafenib in HCC.
Conclusions:
- A novel DBN1-NF2-LATS signaling axis regulating Hippo pathway activity in cancer was identified.
- Pharmacological inhibition of DBN1 represents a promising therapeutic strategy targeting the Hippo pathway for cancer treatment.
- Targeting DBN1 offers a new avenue for intervention in cancers driven by dysregulated Hippo signaling.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
Canonical Wnt Signaling Pathway
Abnormal Proliferation
Intracellular Signaling Affects Focal Adhesions
Some...
Generation of Straight or Branched Actin Filaments
Arp2/3 Complex
Arp2/3 complex is a seven-subunit complex consisting of two proteins similar to actin- Arp2 and Arp3, and five other subunits that help keep Arp2 and Arp3 inactive. When required, the complex is...
Actin Filament Depolymerization
In F-actin, the ADF/cofilin proteins...

